Global Startups Insights
Lets your startup
Funding News, San Francisco, USA Startup Funding News

Circle Pharma Raises $92.5M Series E to Advance Cancer Drug CID-165 Toward Clinical Trials

September 19, 2026
By
Loren Baker
Circle Pharma Raises $92.5M Series E to Advance Cancer Drug CID-165 Toward Clinical Trials

Circle Pharma, a clinical-stage biotech company focused on developing new cancer treatments, has raised $92.5 million in Series E funding. The round was led by The Column Group, with participation from new and existing investors including Nextech Invest, RA Capital Management, Euclidean Capital, and Eli Lilly and Company.

Circle Pharma will use the funding to advance CID-165, an oral drug candidate being developed for ER-positive breast cancer, through early clinical trials. The company will also use part of the funding to continue developing other cancer treatments in its pipeline.

“This financing marks a significant milestone as we execute upon our vision of harnessing the power of macrocycles to transform the treatment of cancer,” said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. “Momentum around our cyclin D1 program has continued to build as CID-165 advances toward the clinic. We believe CID-165 has the potential to become a new backbone therapy for ER-positive breast cancer and this financing provides us with the resources to generate meaningful clinical data to validate that potential. Progress across our pipeline underscores the ability of our platform to generate first-in-class compounds across the previously undrugged family of cyclins, the master regulators of the cell cycle. We are grateful for the commitment and support of our existing and new investors.”

“Cyclin D1 is a well-established driver of cancer, especially in ER-positive breast cancer where there is a lineage dependency on this cyclin, but directly targeting it has remained a longstanding challenge,” said Marie Evangelista, Ph.D., chief scientific officer at Circle Pharma. “CID-165 is designed to selectively disrupt the interaction between cyclin D1 and retinoblastoma protein, providing a novel approach to directly targeting this fundamental driver of tumor growth. The robust activity we have observed across preclinical models in ER-positive breast cancer, both as a monotherapy and in combination with established treatments, gives us strong conviction in the potential of CID-165 as we prepare to advance the program into the clinic in the first quarter of 2027.”

Circle Pharma is a biotech company developing new targeted treatments for cancer and other serious diseases. Its technology uses macrocycles, a type of molecule that can help create medicines that reach difficult targets inside cells.

The company’s MXMO™ platform is designed to help develop medicines that can enter cells and be taken orally, including treatments for targets that have been difficult to address with existing drugs. Circle Pharma is mainly developing treatments that target cyclins, proteins that control cell growth and play a role in many cancers. The company is based in South San Francisco, California.

Recommended Stories for You